Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
about
Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndromeAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderEmerging pharmacologic treatment options for fragile X syndromeTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesComparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in miceGABAergic alterations in neocortex of patients with pharmacoresistant temporal lobe epilepsy can explain the comorbidity of anxiety and depression: the potential impact of clinical factorsGABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy.Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule.Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.GABAB receptor upregulates fragile X mental retardation protein expression in neuronsR-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder.Challenges in the development of therapeutics for narcolepsy.Regulating hippocampal hyperexcitability through GABAB Receptors.Deficient Sleep in Mouse Models of Fragile X Syndrome.Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.Combination Therapy in Fragile X Syndrome; Possibilities and Pitfalls Illustrated by Targeting the mGluR5 and GABA Pathway Simultaneously.Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.GABAB receptor-mediated feed-forward circuit dysfunction in the mouse model of fragile X syndrome.Of Men and Mice: Modeling the Fragile X Syndrome.Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.
P2860
Q24613296-E2D79894-87AC-4C26-88A9-3CB1D1332AFDQ26781265-666A1E85-3B46-489B-A950-FD48F8D048F7Q26829152-6C5ACC02-F784-4E44-969E-5003CC3F080BQ27023257-3209EF90-A4D2-4303-9598-01FA551B220EQ30539539-C0BB15F4-683C-4DFB-A557-73AEE6AA3691Q30612805-A27E5FC8-CDB1-4C72-BFB5-F87E43A750F3Q33575159-8EE3F7ED-5074-40D5-8D8B-B92279811474Q34431654-1C6BAAE0-8FB1-4F6A-B640-FA25A380E6F9Q34499370-CCBB4962-5A53-4359-8715-3E2423E7C0FCQ35168229-EF7FF6A4-AC3E-4B96-A0C2-380A255B79E8Q35659477-A5B0C4EA-A5DF-476A-84BD-897D9810BDFBQ36077206-13419150-434F-43B6-AD80-8AC03C959462Q38215751-74A292F7-9069-442F-908D-AB47B3DF8F3DQ38684472-2CE7410C-E595-4260-B0E8-55174BEAC595Q39002675-0D35249B-E06F-4C38-9B85-A6C89908B770Q41619835-5D3E401C-028E-4DCD-955D-9A09FEC80288Q42512974-EDB70AE1-1D45-4447-8D48-47C8FDB5CDF8Q47112165-DB852944-6E1C-40BF-9FE3-99405C797014Q47118227-15B50FA0-3E98-41A6-8725-D07D05067131Q47796729-03614796-5FCC-4F92-89F0-74A8D5722FE3Q50573783-C1E62140-AD6A-475E-8A24-64243CB0D745Q53422584-D0FB78A5-034E-45C2-8138-B7C15EC04D46Q55155951-80A7E722-53C0-41AB-ACD2-E4BB22A98D4C
P2860
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Subchronic administration and ...... therapy in fragile X syndrome.
@ast
Subchronic administration and ...... therapy in fragile X syndrome.
@en
type
label
Subchronic administration and ...... therapy in fragile X syndrome.
@ast
Subchronic administration and ...... therapy in fragile X syndrome.
@en
prefLabel
Subchronic administration and ...... therapy in fragile X syndrome.
@ast
Subchronic administration and ...... therapy in fragile X syndrome.
@en
P2093
P2860
P356
P1476
Subchronic administration and ...... therapy in fragile X syndrome.
@en
P2093
David R Hampson
Laura K K Pacey
Sujeenthar Tharmalingam
P2860
P304
P356
10.1124/JPET.111.183327
P407
P577
2011-06-02T00:00:00Z